Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12‐week randomized controlled trial
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽
2019 ◽